2023 - Research.com Neuroscience in Italy Leader Award
His primary areas of investigation include Multiple sclerosis, Internal medicine, Surgery, Magnetic resonance imaging and Central nervous system disease. His study in Multiple sclerosis is interdisciplinary in nature, drawing from both Lesion, Pathology, White matter and Nuclear medicine. The study incorporates disciplines such as Gastroenterology, Placebo, Placebo-controlled study and Cardiology in addition to Internal medicine.
The Surgery study combines topics in areas such as Interferon beta-1a, Adverse effect, Teriflunomide, Hazard ratio and Clinically isolated syndrome. His study in the fields of Diffusion MRI under the domain of Magnetic resonance imaging overlaps with other disciplines such as In patient. His studies deal with areas such as Predictive value of tests, Magnetization transfer, Radiology, Neurology and Optic neuritis as well as Central nervous system disease.
His scientific interests lie mostly in Multiple sclerosis, Internal medicine, Neuroscience, Magnetic resonance imaging and Pathology. His study looks at the relationship between Multiple sclerosis and topics such as Nuclear medicine, which overlap with Magnetization transfer. His studies in Internal medicine integrate themes in fields like Surgery, Oncology, Gastroenterology, Expanded Disability Status Scale and Placebo.
His work deals with themes such as Clinical trial, Adverse effect, Randomized controlled trial, Teriflunomide and Cladribine, which intersect with Placebo. His Magnetic resonance imaging study incorporates themes from Neurology and Neuroradiology. His research investigates the connection with Pathology and areas like White matter which intersect with concerns in Corpus callosum, Atrophy and Audiology.
Giancarlo Comi mainly investigates Multiple sclerosis, Internal medicine, In patient, Clinical trial and Disease. His Multiple sclerosis research incorporates elements of Alemtuzumab, Cladribine, Magnetic resonance imaging, Neuroscience and Pediatrics. His research integrates issues of Gastroenterology, Placebo, Expanded Disability Status Scale and Oncology in his study of Internal medicine.
His Placebo research is multidisciplinary, relying on both Tolerability, Teriflunomide and Phases of clinical research. His work in Clinical trial is not limited to one particular discipline; it also encompasses Randomized controlled trial. His Family medicine research includes themes of Clinical investigation and Ofatumumab.
Multiple sclerosis, Internal medicine, Placebo, Disease and Expanded Disability Status Scale are his primary areas of study. His Multiple sclerosis research is multidisciplinary, incorporating perspectives in Disease activity, White matter, Magnetic resonance imaging, Alemtuzumab and Pediatrics. In his work, Young adult and Biomarker is strongly intertwined with Gastroenterology, which is a subfield of Internal medicine.
His Placebo research integrates issues from Tolerability, Adverse effect, Cladribine and Lymphocyte. Giancarlo Comi has included themes like Connectome, Brain network and Epidemiology in his Disease study. His Expanded Disability Status Scale research is multidisciplinary, relying on both Odds ratio, Clinical endpoint, Proportional hazards model, Age of onset and Cohort.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson;Brenda L. Banwell;Frederik Barkhof;Frederik Barkhof;William M. Carroll.
Lancet Neurology (2017)
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer;Garrett Hellenthal;Matti Pirinen;Chris C. A. Spencer.
Defining the clinical course of multiple sclerosis: The 2013 revisions
Fred D. Lublin;Stephen C. Reingold;Jeffrey A. Cohen;Gary R. Cutter.
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.
Frederik Barkhof;Massimo Filippi;David H. Miller;Philip Scheltens.
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.
Giancarlo Comi;Massimo Filippi;Frederik Barkhof;Luca Durelli.
The Lancet (2001)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold.
The New England Journal of Medicine (2017)
Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis
Stefano Pluchino;Angelo Quattrini;Elena Brambilla;Angela Gritti.
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Ludwig Kappos;Jack Antel;Giancarlo Comi;Xavier Montalban.
The New England Journal of Medicine (2006)
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
Ashley H. Beecham;Nikolaos A. Patsopoulos;Nikolaos A. Patsopoulos;Dionysia K. Xifara;Mary F. Davis.
Nature Genetics (2013)
European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis
Giancarlo Comi;Massimo Filippi;Jerry S. Wolinsky.
Annals of Neurology (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: